SCHEMBL14718592

SCHEMBL14718592

O=c1[nH]nc(CCc2c(F)cccc2Cl)cc1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 2/20 0.51
TAAR1 Q96RJ0 1/20 0.44
LMNA P02545 2/20 0.43
AKR1B1 P15121 1/20 0.43
MAPT P10636 2/20 0.41
TP53 P04637 1/20 0.41
LCK P06239 1/20 0.41
BTK Q06187 1/20 0.41
MAPK14 Q16539 1/20 0.41
GAA P10253 2/20 0.40
KDM4E B2RXH2 3/20 0.40
COMT P21964 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
HSD17B10 Q99714 1/20 0.40
AR P10275 2/20 0.39
P2RX7 Q99572 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30159723 1.00 DAO (0.51) DAOTAAR1LMNAAKR1B1MAPT
SCHEMBL14718767 0.91 DAO (0.46) DAOLMNAAKR1B1KDM4ECOMT
SCHEMBL14719577 0.88 DAO (0.50) DAOLMNAAKR1B1MAPTTP53
SCHEMBL14729688 0.85 DAO (0.39) DAOLMNAAKR1B1KDM4EAR
SCHEMBL16231919 0.81 AR (0.44) DAOLMNAMAPTLCKMAPK14
SCHEMBL16231909 0.79 DAO (0.36) DAOTAAR1AR
SCHEMBL16231893 0.79 CXCR2 (0.46) DAOAKR1B1AR
SCHEMBL14718729 0.79 DAO (0.48) DAOLMNAMAPTARP2RX7
SCHEMBL30159731 0.79 DAO (0.48) DAOLMNAMAPTARP2RX7
SCHEMBL30159720 0.79 DAO (0.57) DAOTAAR1AKR1B1KDM4EAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10463663-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-11-05 US claimed
US-20180177780-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-06-28 US claimed
EP-3113778-B1 PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTION OR TREATMENT OF AN ATAXIC DISORDER TAKEDA PHARMACEUTICALS CO (JP) 2018-06-06 EP claimed
US-9931340-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-04-03 US claimed
EP-2748149-B9 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICALS CO (JP) 2017-11-15 EP claimed
US-20170173007-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-06-22 US claimed
US-20170014407-A1 PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTON OR TREATMENT OF AN ATAXIC DISORDER TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-01-19 US claimed
EP-3113778-A1 PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTION OR TREATMENT OF AN ATAXIC DISORDER Takeda Pharmaceutical Company Limited (JP) 2017-01-11 EP claimed
US-9290456-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-03-22 US claimed
EP-2748149-B1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2015-10-21 EP claimed
WO-2015132608-A1 PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTION OR TREATMENT OF AN ATAXIC DISORDER TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-11 WO claimed
US-20150030704-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-01-29 US claimed
EP-2748149-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2014-07-02 EP claimed
US-20130052281-A1 NOVEL COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 US claimed
WO-2013027000-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 WO claimed
US-12186313-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-01-07 US disclosed
US-20220008416-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-01-13 US disclosed
US-20130052281-A1 NOVEL COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 US disclosed
US-20130052281-A1 NOVEL COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 US disclosed
US-20130052281-A1 NOVEL COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130052281-A1 NOVEL COMPOUNDS ABCG2, F12, UGT1A1 DAO 4565/4885TAAR1 1008/4885LMNA 3558/4885
US-20150030704-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD DAO 2/4885TAAR1 638/4885LMNA 1655/4885
US-20170014407-A1 PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTON OR TREATMENT OF AN ATAXIC DISORDER ATXN2, CLN6, ATXN10 DAO 1144/4885TAAR1 328/4885LMNA 1408/4885
US-12186313-B2 Pyridazinone compounds and their use as DAAO inhibitors PNPO, DAO, DPYD DAO 2/4885TAAR1 638/4885LMNA 1655/4885
US-20180177780-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD DAO 2/4885TAAR1 638/4885LMNA 1655/4885
US-10463663-B2 Pyridazinone compounds and their use as DAAO inhibitors PNPO, DAO, DPYD DAO 2/4885TAAR1 638/4885LMNA 1655/4885
US-20170173007-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD DAO 2/4885TAAR1 638/4885LMNA 1655/4885
US-20220008416-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD DAO 2/4885TAAR1 638/4885LMNA 1655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.